Press Room

Article / May 04, 2004

Do we really need more trade-shows

BioFine Berlin, 4 May 2004

Hovione will be in at the 1st BioFine event in Berlin, so yes we did feel there was space for another show. In fact our thoughts are that some shows may have become too large and far too expensive, trying to be all things to all people, and with their gigantic size working against some of their users. Many of us, tired and with sore feet, wonder why we have to stand in queues waiting for expensive average food. We are looking at Bio-fine as a differentiated show - one that focuses away from commodities and is sensitive to pairing customers with suppliers eager to provide service and know-how.

In giving our best wishes to the managers of BioFine, we would remind them that this is a global industry where English is the lingua franca and the outlook is international. We all have full agendas and tight schedules so please do choose venues where foreigners are welcome, taxis cheap and plentiful, airports near-by and hotels at the convention centre and not a wet 5 (in fact 15) minute walk away! Please time your shows away from other well-established and popular industry events, do consider traditional holidays of the key nations involved, keep away from locations in seasons that are predictably wet and cold. A great show was CPhI 1997 in London in Earl´s Court - everyone spoke English, the walk to the tube was 2 minutes, it was sunny September, and close to all the hotels.

If Bio-fine wants to do really well look to how organisers of US shows do it. Food is free, no queues, no wet walks - and it is inexpensive. Charging attendees makes sure the quality stays high; keeping it small and with a smart market positioning makes sure the right people show up, business is done and time is not wasted. Going forward, security concerns are also a factor, keeping away from big crowds or major cities may be a plus.

At BioFine we will be offering our customers the latest technology we have added to our capabilities: particle size design, from lab to large-scale, with a focus on reproducibility of physical characteristics. Our customers tell us that the galenic interface is where most of our competitors fail. We are doing for particle size and crystal form what we did for injectable grade APIs in the 90´s, becoming a leader and defining bench-marks.

Guy Villax
CEO Hovione
Loures, 4th May 2004

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026